Clozapine, GABA(B), and the treatment of resistant schizophrenia.
Daskalakis
Z J
ZJ
Department of Psychiatry, Schizophrenia Program, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada. Jeff_Daskalakis@camh.net
George
T P
TP
D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001418:Baclofen / Q000494:pharmacology / Q000627:therapeutic use; D003024:Clozapine / Q000494:pharmacology* / Q000627:therapeutic use; D004351:Drug Resistance; D018755:GABA Agonists / Q000494:pharmacology / Q000627:therapeutic use; D018756:GABA Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012907:Smoking / Q000503:physiopathology; D014029:Tobacco Use Disorder / Q000503:physiopathology; D050781:Transcranial Magnetic Stimulation; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D014150:Antipsychotic Agents; D018755:GABA Agonists; D018756:GABA Antagonists; D005680:gamma-Aminobutyric Acid; D001418:Baclofen; D003024:Clozapine